INMD — InMode Ltd.

InMode (INMD) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Revenue: $93.2 million, down from $130.2 million in Q3 2024 (which included $31.9 million in preorder sales).
• Consumables and Service Revenues: $19.9 million, a 26% year-over-year increase, primarily driven by international markets.
• Geographical Breakdown:
  • U.S. sales: $53.2 million
  • International sales: $40 million (43% of total sales), a 10% year-over-year increase.
• Gross Margin: 78%, down from 82% in Q3 2024, impacted by tariffs.
• Operating Expenses: GAAP operating expenses decreased to $51.4 million (11% year-over-year decrease).
• Net Income: GAAP net income of $21.8 million, down from $50.9 million in Q3 2024.
• Earnings Per Share: GAAP diluted EPS of $0.34, down from $0.65 in Q3 2024.
• Cash Position: $532.3 million in cash and equivalents as of September 30, 2025.

2. Strategic Updates and Business Highlights:

• Global Expansion: Opened a new subsidiary in Argentina and continued growth in Thailand, aiming to enhance local customer engagement.
• Men's Wellness Platform: Full commercial rollout occurred in Q3, with anticipated revenue contribution by year-end.
• Leadership Changes: Michael Dennison appointed as President of North America, consolidating regional management to streamline operations.
• Ophthalmology Initiative: Progressing towards FDA clearance for dry eye treatment, with plans for clinical studies in 2026.

3. Forward Guidance and Outlook:

• 2025 Revenue Guidance: Expected to remain between $365 million to $375 million.
• Gross Margin Guidance: Non-GAAP gross margins projected between 78% to 80%.
• Earnings Guidance: Non-GAAP earnings per diluted share expected between $1.55 to $1.59.
• Cautious Outlook for 2026: Management indicated a conservative approach to 2026 guidance due to market uncertainties.

4. Bad News, Challenges, or Points of Concern:

• Declining Metrics: Significant year-over-year declines in revenue, net income, and EPS compared to Q3 2024.
• Market Environment: Ongoing challenges in capital equipment sales due to high interest rates, particularly affecting clinics.
• Competitive Pressures: Need for differentiation in a crowded aesthetic market, especially in noninvasive products.

5. Notable Q&A Insights:

• Sales Growth Concerns: CFO Yair Malca noted uncertainties in the market may lead to conservative sales growth expectations for 2026.
• Interest Rates Impact: While interest rates have decreased, the impact on capital equipment financing remains limited, affecting sales.
• Ophthalmology Strategy: Plans to separate sales teams for ophthalmology and aesthetics to enhance focus and effectiveness.
• Consumables Growth: Sold approximately 230,000 disposable handpieces in Q3, indicating a sequential increase and positive trend in consumables.

Overall, while InMode demonstrated resilience with strategic expansions and product rollouts, the financial results reflected significant year-over-year declines, prompting cautious guidance for the upcoming year amidst a challenging market environment.